BioMark Diagnostics Inc. (BMKDF)
USD 0.15
(0.0%)
USD 0.15
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 163.22 Thousand CAD | -91.34% |
| 2023 | 1.88 Million CAD | 30.31% |
| 2022 | 1.44 Million CAD | 33.66% |
| 2021 | 1.08 Million CAD | -26.47% |
| 2020 | 1.47 Million CAD | 169.85% |
| 2019 | 545.61 Thousand CAD | -24.92% |
| 2018 | 726.74 Thousand CAD | 0.8% |
| 2017 | 721 Thousand CAD | -48.78% |
| 2016 | 1.4 Million CAD | -51.2% |
| 2015 | 2.88 Million CAD | 1493.6% |
| 2014 | 180.99 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 371.6 Thousand CAD | -27.37% |
| 2024 Q2 | 385.89 Thousand CAD | 3.85% |
| 2024 Q3 | 383.04 Thousand CAD | -0.74% |
| 2024 FY | 1.57 Million CAD | -16.38% |
| 2024 Q4 | 436.2 Thousand CAD | 13.88% |
| 2023 Q1 | 426.78 Thousand CAD | -40.49% |
| 2023 Q4 | 511.64 Thousand CAD | 25.31% |
| 2023 Q2 | 538.83 Thousand CAD | 26.25% |
| 2023 Q3 | 408.3 Thousand CAD | -24.22% |
| 2023 FY | 1.88 Million CAD | 30.31% |
| 2022 FY | 1.44 Million CAD | 33.66% |
| 2022 Q4 | 717.11 Thousand CAD | 169.21% |
| 2022 Q3 | 266.37 Thousand CAD | 49.72% |
| 2022 Q2 | 177.92 Thousand CAD | -37.71% |
| 2022 Q1 | 285.62 Thousand CAD | -49.87% |
| 2021 Q4 | 569.81 Thousand CAD | 193.43% |
| 2021 FY | 1.08 Million CAD | -26.47% |
| 2021 Q1 | 131.18 Thousand CAD | -53.09% |
| 2021 Q3 | 194.18 Thousand CAD | 3.59% |
| 2021 Q2 | 187.45 Thousand CAD | 42.89% |
| 2020 Q1 | 120.55 Thousand CAD | -2.16% |
| 2020 Q4 | 279.67 Thousand CAD | -70.13% |
| 2020 Q2 | 135.92 Thousand CAD | 12.75% |
| 2020 FY | 1.47 Million CAD | 169.85% |
| 2020 Q3 | 936.17 Thousand CAD | 588.74% |
| 2019 Q3 | 168.66 Thousand CAD | 5.05% |
| 2019 FY | 545.61 Thousand CAD | -24.92% |
| 2019 Q4 | 123.21 Thousand CAD | -26.95% |
| 2019 Q2 | 160.55 Thousand CAD | 44.76% |
| 2019 Q1 | 110.91 Thousand CAD | -21.83% |
| 2018 Q2 | 218.42 Thousand CAD | 14.92% |
| 2018 Q3 | 176.37 Thousand CAD | -19.25% |
| 2018 Q4 | 141.88 Thousand CAD | -19.56% |
| 2018 FY | 726.74 Thousand CAD | 0.8% |
| 2018 Q1 | 190.06 Thousand CAD | -21.91% |
| 2017 Q3 | 111.75 Thousand CAD | -25.65% |
| 2017 FY | 721 Thousand CAD | -48.78% |
| 2017 Q4 | 243.4 Thousand CAD | 117.8% |
| 2017 Q2 | 150.3 Thousand CAD | -30.26% |
| 2017 Q1 | 215.53 Thousand CAD | -69.24% |
| 2016 Q3 | 260.89 Thousand CAD | 10.27% |
| 2016 Q2 | 236.59 Thousand CAD | 13.05% |
| 2016 Q1 | 209.29 Thousand CAD | -70.36% |
| 2016 Q4 | 700.74 Thousand CAD | 168.6% |
| 2016 FY | 1.4 Million CAD | -51.2% |
| 2015 Q1 | 65.99 Thousand CAD | 0.0% |
| 2015 Q2 | 51.4 Thousand CAD | -22.11% |
| 2015 Q3 | 2.05 Million CAD | 3907.0% |
| 2015 Q4 | 706.11 Thousand CAD | -65.72% |
| 2015 FY | 2.88 Million CAD | 1493.6% |
| 2014 FY | 180.99 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | 84.44% |
| Arrayit Corporation | 6.19 Million USD | 97.366% |
| Atlantic International Corp. | 5.57 Million USD | 97.074% |
| Biocept, Inc. | 29.4 Million USD | 99.445% |
| Bioqual, Inc. | 7.44 Million USD | 97.809% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | 78.861% |
| DermTech, Inc. | 104.01 Million USD | 99.843% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 99.902% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 99.279% |
| iMD Companies, Inc. | 151.8 Thousand USD | -7.517% |
| IDenta Corp. | 662.97 Thousand USD | 75.381% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 99.193% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -319.794% |
| InVitro International | 661.32 Thousand USD | 75.319% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 97.7% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -180.871% |
| Medical Imaging Corp. | 1.91 Million USD | 91.464% |
| NovelStem International Corp. | 3.53 Million USD | 95.386% |
| Optigenex Inc. | 1.28 Million USD | 87.326% |
| PharmChem, Inc. | 2.93 Million USD | 94.432% |
| Proteome Sciences plc | 3.26 Million USD | 95.006% |
| Response Genetics, Inc | 25.31 Million USD | 99.355% |
| Rennova Health, Inc. | 7.67 Million USD | 97.874% |
| RushNet, Inc. | 1.78 Million USD | 90.878% |
| ScreenPro Security Inc. | 3.23 Million USD | 94.961% |
| Stella Diagnostics Inc. | 11.42 Million USD | 98.572% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 97.777% |
| Todos Medical Ltd. | 14.05 Million USD | 98.839% |